Ortho Clinical Diagnostics Holdings Plc (OCDX) Growth Rates Comparisons to In Vitro & In Vivo Diagnostic Substances Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Ortho Clinical Diagnostics Holdings Plc  (NASDAQ: OCDX)
 

Ortho Clinical Diagnostics Holdings Plc Growth Comparisons

Select each growth Category to receive further Information





OCDX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) -1.32 % 41.64 % 14.64 % 14.5 %
Q / Q Revenue Growth (Q1 MRQ) -4.01 % 423.98 % 0.69 % -1.48 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 9.17 % 50.26 % 22.94 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) -0.33 % 12.73 % 3.22 % 3 %
Revenue 5 Year Average Growth - 14.5 % 12.9 % 12.72 %


OCDX's Growth Comparisons in I. Quarter 2022




Although the In Vitro & In Vivo Diagnostic Substances industry saw advancing Revenue by 41.64%, Ortho Clinical Diagnostics Holdings Plc announced -1.32% year on year sales decline in the first quarter 2022, to $ 500 millions, and underperformed the 14.64% Revenue improvement in the Healthcare sector. Although both In Vitro & In Vivo Diagnostic Substances industry and Healthcare sector posted higher gains than 14.5% overall market increase, Ortho Clinical Diagnostics Holdings Plc was trailing overall market in the first quarter.

Top-line fell by -4.01% from the fourth quarter. Average annual sales growth for Ortho Clinical Diagnostics Holdings Plc is %, while S & P 500's average yearly sales increase is 12.72%, including only Businesses with the first quarter 2022 financial results.


Growth Rates of OCDX's Income in the first quarter 2022


OCDX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) -17.94 % 81.4 % 4.03 % 14.73 %
Sequential Operating Income Change (Q1 MRQ) - 277.87 % -6.41 % -12.7 %
Y / Y Operating Income Growth (Q1 TTM) - 117.77 % 60.84 % 59.76 %
Sequential Operating Income Growth (Q1 TTM) - 31.05 % 2.47 % 2.49 %
Operating Income 5 Year Avg. Change - 19.97 % 11.58 % 16.54 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - 139.65 % -30.86 % 12.59 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - 151.08 % -29.83 % 3.2 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - 9.41 % 72.59 % 63.82 %
Sequential Income from Cont. Ops. Change (Q1 TTM) - 35 % -5.75 % 0.34 %
Income from Cont. Ops. 5 Year Avg. Change - 34.06 % 20.87 % 23.18 %

OCDX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - 131.34 % -31.41 % 13.8 %
Q / Q Net Income Growth (Q1 MRQ) - 84.87 % -33.8 % 3.68 %
Y / Y Net Income Change (Q1 TTM) - 9.41 % 76.53 % 67.8 %
Sequential Net Income Change (Q1 TTM) - 35 % -5.76 % 0.66 %
Net Income 5 Year Avg. Growth - 33.96 % 20.57 % 22.5 %

OCDX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - 122.23 % -30.86 % 12.59 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - 119.47 % -29.83 % 3.2 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - 6640.43 %
EPS from Cont. Ops. 5 Year Avg. Growth - 25.71 % 20.87 % 23.18 %



OCDX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - 114.53 % -31.41 % 23.18 %
Q / Q EPS Net Growth (Q1 MRQ) - 61.6 % -33.8 % 3.68 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - 20.37 % - 40036.37 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - 165.08 % - 55.38 %
EPS Net 5 Year Avg. Change - 33.96 % 20.57 % 22.5 %



Ortho Clinical Diagnostics Holdings Plc reported bottom-line of $ 0.06 in the first quarter, compare to $ -0.19 in the same quarter a year ago. In Vitro & In Vivo Diagnostic Substances industry grew by 114.53%, while Healthcare sector decreased by -31.41%, and overall market improved by 13.8%.

the bottom-line fell by -4.01% from the fourth quarter. Average annual income per share growth for Ortho Clinical Diagnostics Holdings Plc is %, while S & P 500's average yearly income per share increase is 22.5%, including only Businesses with the first quarter 2022 earnings.

OCDX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) - -47.75 % -24.93 % -0.56 %
Sequential Free Cash Flow Change (Q1 MRQ) - -15.45 % -37.68 % -42.06 %
Y / Y Free Cash Flow Change (Q1 TTM) 1441.96 % -37.99 % 10.74 % 35.72 %
Sequential Free Cash Flow Change (Q1 TTM) -3.37 % -12.77 % -0.09 % -3.7 %
Free Cash Flow 5 Year Avg. Change - 14.29 % 18.33 % 35.41 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - -67.14 % - -
Sequential Net Cash Flow Change (Q1 MRQ) - - - -
Y / Y Net Cash Flow Change (Q1 TTM) 483.74 % - - -85.17 %
Sequential Net Cash Flow Change (Q1 TTM) - - - -60.83 %
Net Cash Flow 5 Year Avg. Change - - 87.74 % 114.76 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) 101.49 % -14.47 % 13.19 % 11.66 %
Sequential Capital Expenditures Change (Q1 MRQ) -13.46 % 4.99 % -29.51 % -22.93 %
Y / Y Capital Expenditures Change (Q1 TTM) 82.74 % 79.43 % 11.5 % 20.71 %
Sequential Capital Expenditures Change (Q1 TTM) 23.29 % -5.02 % 1.75 % 2.76 %
Capital Expenditures 5 Year Avg. Change - 40.07 % 11.68 % 14.84 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.